Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists pinpoint optimal sedation dose for safer gastroscopy across ages

NCT ID NCT07678411

Knowledge-focused Sponsor: Shiyou Wei Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study aims to find the 90% effective dose of tegileridine, a painkiller, when combined with propofol for sedation during painless gastroscopy. Researchers will test different doses in young (18-65) and elderly (65+) adults to see which dose best prevents movement, coughing, or blood pressure changes during the procedure. The goal is to improve sedation safety and effectiveness for both age groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tegileridine combined with propofol
What this could lead to
If successful, this could establish a precise, safer sedation dose for gastroscopy in different age groups, reducing side effects.
What could go wrong
This is a small, early-phase dose-finding study, not a large effectiveness trial. Results may not apply to all patients or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

107 people

The number who actually took part.

Started

Jul 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Outpatients scheduled for elective painless gastroscopy * Age ≥ 18 years old * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) between 18.5 and 29.9 kg/m² Exclusion Criteria: * Resting SBP ≥ 160 mmHg, DBP ≥ 110 mmHg, or heart rate ≥ 110 beats/min on admission to endoscopy room * Continuous opioid medication use for more than 2 weeks within 6 months before the procedure * Known hypersensitivity or allergic reaction to tegileridine, propofol or any excipients of the two drugs * Diagnosed psychiatric disorders or inability to communicate and cooperate with study assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Painless gastroscopy perioperative sedation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

upper digestive tract disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Painless gastroscopy perioperative sedation Upper gastrointestinal tract lesions

Contacts and locations

Locations

  • Tianmen First People's Hospital, Affiliated Hospital of Wuhan University of Science and Technology

    Tianmen, Hubei, 431700, China